Investing.com -- Septerna, Inc. (NASDAQ: SEPN ), a biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, saw its shares fall 4.3% after reporting a widened net loss for ...

While revenue declined, GoPro’s gross margin improved substantially to 36.0% from 30.7% in the same quarter last year, a 530 ...

Investing.com -- Harvard University and the Trump administration are close to reaching a $500 million settlement that would end their legal dispute and restore billions in federal research funding to ...

Investing.com -- Gevo , Inc. (NASDAQ: GEVO) shares surged 47.2% after the renewable fuels company reported its first-ever quarterly profit, beating analyst expectations with strong revenue growth ...

DALLAS - Celanese Corporation (NYSE: CE) shares fell 11.2% after the global chemical and specialty materials company issued a disappointing third-quarter outlook that overshadowed better-than-expected ...

SAN DIEGO - Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) reported a significant revenue shortfall in the second quarter as the company continues to advance its pipeline of mRNA therapeutics and ...

The company reported an adjusted EBITDA of $17.2 million, up 6.2% from $16.2 million in the second quarter of 2024, despite the revenue decline. RumbleOn also reduced its selling, general and ...

The media company posted revenue of $933.7 million for the quarter ended June 30, 2025, surpassing the consensus estimate of $912.4 million and representing a 0.5% increase YoY. Adjusted EBITDA rose 3 ...

Investor sentiment turned positive following the results, with shares moving higher in after-hours trading. With a $15.7 ...

Investing.com -- Eastman Kodak Company (NYSE: KODK) shares tumbled 10% after the company reported a significant earnings decline, swinging to a net loss in the second quarter of 2025 as it continues ...

For fiscal year 2025, Hillenbrand updated its revenue guidance to $2.595-$2.630 billion, above the consensus estimate of $2.58 billion. The company maintained its adjusted EPS outlook at $2.20-$2.35, ...

Investing.com -- Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares surged 6.4% after the neuroscience-focused biopharmaceutical company reported second-quarter earnings that dramatically exceeded ...